Sanofi and Regeneron Expand Alliance With $1 Billion Upfront, Up to $7 Billion in Milestones for Four New Immunology Antibodies

Sanofi and Regeneron announced on Oct. 1, 2026 an expansion of their two-decade-old antibody alliance, adding four next-generation, long-acting, Regeneron-invented antibodies aimed at immunology targets including interleukin-13 (IL-13), interleukin-4 (IL-4), IL-4 receptor alpha (IL-4Rα) and an IL-4xIL-13 bispecific. Regeneron will receive $1 billion upfront from Sanofi, with potential development, regulatory and commercial milestone payments of up to an additional $7 billion, according to the joint Sanofi-Regeneron press release.

Based on the disclosed figures, the deal's combined potential value is as much as $8 billion ($1 billion upfront plus up to $7 billion in milestones), a calculation derived directly from the companies' own terms rather than a figure stated outright in the release.

Deal Structure: Shared Costs, 50:50 Profit Split

Under the agreement, Sanofi and Regeneron will co-develop and co-commercialize the four new antibodies, sharing development and commercialization costs and splitting future profits from any resulting products 50:50 on a global basis. Regeneron will lead research and development activities, while Sanofi will lead global commercial efforts, according to the release. The companies specified that the existing profit-sharing arrangement covering Dupixent, their flagship immunology medicine, will not change as a result of this expansion.

The press release did not disclose how the new milestone payments are triggered beyond the general categories of development, regulatory and commercial events, nor did it specify any changes to Regeneron's research and development expense outlook or Sanofi's broader financial guidance.

Four Antibodies, Staggered Development Timelines

The most advanced of the four assets is REGN20423, a long-acting IL-13 monoclonal antibody invented and developed by Regeneron, which is currently in a Phase 1 clinical study for atopic dermatitis. The remaining three programs, a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies, are expected to enter clinical studies in 2027, per the companies' disclosure.

Separately, Regeneron secured an option to bring Sanofi's lunsekimig, an investigational bispecific Nanobody VHH therapy targeting TSLP and IL-13, into the collaboration. That option becomes exercisable once lunsekimig completes its Phase 3 studies in chronic obstructive pulmonary disease, the release said.

The companies also disclosed that they have settled prior collaboration-related litigation, though the release did not detail the nature or terms of that litigation.

Building on the Dupixent Partnership

Sanofi and Regeneron frame the expanded deal as an extension of a clinical and commercial alliance dating to 2003, one that has produced multiple approved medicines including Dupixent. According to the companies, more than 1.5 million people are currently receiving Dupixent across nine indications, making it one of the most widely used antibody medicines globally.

Regeneron CEO Leonard S. Schleifer said in the release, “By expanding our Alliance, we are positioning promising new long-acting antibodies for the kind of rapid, global impact that our shared work on Dupixent has already achieved.” Regeneron chief scientific officer George D. Yancopoulos, a principal inventor of Dupixent, said the companies hope “to once again deliver the next wave of innovation in immunology.” Sanofi CEO Belén Garijo described the transaction as “a deliberate first step in igniting Sanofi's innovation engine.”

What the Companies Did Not Disclose

The joint release did not include same-day market reaction data, updated analyst estimates, or specific changes to either company's financial guidance tied to this agreement. Sanofi and Regeneron said they would host a joint conference call for investors and analysts on Oct. 1 at 14:00 CET/8:00 a.m. ET, according to the release; the contents of that call are not part of the companies' written disclosure.

Regeneron also included a cautionary note typical of collaboration announcements, stating that the amended license and collaboration agreement with Sanofi could be cancelled or terminated without realizing its expected benefits, and that regulatory approval, timing and the eventual commercial success of the new antibody candidates remain uncertain. That caveat applies to the entire slate of newly added programs, given that three of the four assets have not yet entered human clinical testing.

Bottom Line

Sanofi and Regeneron have widened a relationship that already produced Dupixent, committing $1 billion upfront and up to $7 billion in potential milestones to four long-acting immunology antibodies, most of which remain in early or pre-clinical stages. The companies preserved the existing Dupixent economics while establishing a new 50:50 profit split for the added programs, with Regeneron driving research and Sanofi leading commercialization. Whether this expansion translates into approved medicines, and how it factors into either company's longer-term financial picture, will depend on clinical results still years away and was not addressed in the companies' Oct. 1 disclosure.